Hot Trades Closing the Day on a High Note

February 12, 2025

DENVER, Colo., Feb 12, 2025 (247marketnews.com)- 24/7 Market News, a trusted source for real-time financial news and market analysis, highlights today’s most significant stock movements and breaking developments shaping the financial landscape.

Xilio Therapeutics (NASDAQ:XLO) entered into a collaboration and option-to-license agreement with AbbVie (NYSE:ABBV). The collaboration plans to develop novel tumor-activated, antibody-based immunotherapies, including masked T-cell engagers, by leveraging Xilio’s proprietary tumor-activated biologics platform technology, which is designed to achieve tumor-selective activation and minimize systemic side effects.

Under the agreement, Xilio Therapeutics will receive an upfront payment of $52 million, which includes a $10 million equity investment by AbbVie. Additionally, Xilio is eligible for up to approximately $2.1 billion in total contingent payments. This includes option-related fees, milestone payments, and tiered royalties based on future product sales.

Xilio is trading near today’s high and already surpassed $200 million in trading volume for the day.

NKGen Biotech (NASDAQ:NKGN) announced, this morning, that the FDA granted Fast Track designation for its investigational therapy, troculeucel, an ex vivo expanded autologous NK (natural killer) cell therapy, for the treatment of moderate Alzheimer’s disease (AD). The Fast Track designation is a process designed to facilitate the development and review of drugs that address serious conditions with unmet medical needs, potentially allowing faster access to promising treatments.

NKGen Biotech is even better positioned to close at today’s high, but on much less volume than Xilio.

Firefly Neuroscience (NASDAQ:AIFF) is following through yesterday’s announcement that it was accepted into the NVIDIA Connect program. Firefly plans to use these new tools and resources to help support a new strategic initiative to build a proprietary foundation model of the human brain. Firefly will trade over 90 million shares for the day and has a new 52-week high within its sights.

Aptose Biosciences (NASDAQ:APTO) reported promising early safety and response results, this morning, from its Phase 1/2 TUSCANY trial, evaluating tuspetinib in combination with venetoclax (VEN) and azacitidine (AZA) (TUS+VEN+AZA) for the treatment of newly diagnosed acute myeloid leukemia (AML). The 40 mg dose of tuspetinib combined with standard of care therapies is showing early efficacy and a manageable safety profile in patients who are ineligible for induction chemotherapy. Aptose has already eclipsed 125 million shares traded on the day.

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (ABBV, XLO, APTO, NKGN, AIFF)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.